EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Tissue-based biomarkers: CCP

London, England (UroToday.com) Prostate cancer is a major cause of death. Dr. Cuzick described his research looking at the actual samples of the biopsies assessing a whole range of markers. The focus of today’s presentation was the cell cycle progression score (CCP), based on 31 cell cycle progression genes, and its correlation to prostate cancer specific death. A large cohort of men with localized prostate cancer diagnosed by TURP surgery or by biopsy was used for various studies examining the role of CCP.

It was demonstrated that one unit change in the CCP score resulted in a 2 times risk increase for prostate cancer death, with 80% death rate at high scores and almost no death at a CCP score of less than 0. In multivariate analysis incorporating PSA, Gleason score and CCP score, it was shown that CCP is the most dominant factor. Further studies in various subsets of prostate cancer patients demonstrated similar results with CCP being the more significant prognostic factor.

When comparing the CCP score to other scores such as the CAPRA score, the CCP score by itself had a 2 fold increase in risk in the univariate analysis, which was higher than CAPRA. Additionally, in the multivariate analysis the CCP continued to be the strongest predictor of prostate cancer death.

To conclude, CCP provides critical information about prognosis in biopsies and TURP/radical prostatectomy pathologies in various clinical settings of the disease. It may have a central role in determining which patients with a Gleason 6 or Gleason 7 (3+4) might require radical treatment.

Presented by: Jack Cuzick, London (GB)

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto

Twitter: @GoldbergHanan

at the #EAU17 -March 24-28, 2017- London, England

Login